Deft Blog · From the Peptides course, Module 3

The Lizard, the Scientist, and the Blockbuster: The Real GLP-1 Origin Story

You have probably heard that Ozempic comes from Komodo dragon venom. It doesn't — and the true story is better than the myth. It just assigns the credit correctly.

Here is the version that circulates, in a thousand short videos and dinner-party retellings: in the nineties, a scientist discovered a wonder chemical in Komodo dragon venom, and drug companies turned that venom into Ozempic. It has everything a viral story needs — an exotic animal, a lone discovery, a famous drug. It is also wrong in three separate places: the animal, the discovery, and the drug.

The real story starts somewhere less cinematic: inside you, right after lunch.

A hormone with a two-minute life

GLP-1 — glucagon-like peptide-1 — is a hormone your intestine releases after a meal. It tells the pancreas to release insulin when glucose is present, restrains another hormone that raises blood sugar, slows the stomach, and helps produce the feeling that a meal is finished. As metabolic signals go, it is close to ideal.

Except for one flaw. Your body destroys GLP-1 almost immediately. An enzyme called DPP-4 clips it into inactivity, and the kidneys clear what remains. The natural hormone's working life is roughly two minutes.

That is excellent design for a meal signal — you want it to switch off. It is a nightmare for a medicine. A drug that vanishes in two minutes is not a drug; it's a rumour.

Researchers understood the signal long before they could use it. GLP-1 was identified in the 1980s through work on the gene encoding a family of related hormones — work associated with Joel Habener's laboratory — and Svetlana Mojsov's research was central to pinning down the hormone's active form and its effect on insulin. By the end of the decade, the field knew what GLP-1 was and what it did. What it did not have was a way to make the signal last.

Enter the lizard — the right one

In the early 1990s, John Eng, an endocrinologist at the Bronx veterans' hospital in New York, was doing something unfashionable: screening animal venoms for molecules that interact with gut-hormone systems. Venoms are libraries of potent signalling molecules, refined by evolution to act fast and hit hard.

In the venom of the Gila monster — a heavy, orange-and-black lizard of the American Southwest and Mexico — Eng isolated a peptide he called exendin-4. Not a Komodo dragon: the Komodo is a giant Indonesian monitor lizard that has nothing to do with this story, and its appearance in a retelling is a reliable marker that the teller is repeating a rumour rather than a source.

Exendin-4 looked like a cousin of GLP-1: similar enough to activate the same receptor, different in one crucial respect. Where human GLP-1 is clipped by DPP-4 almost on contact, exendin-4 resisted the enzyme. Instead of minutes, it lasted hours.

Notice what Eng did and didn't do. He did not discover GLP-1 — that was human physiology, a decade earlier. He found proof that a GLP-1 signal could be made durable, and a working template for how. The lizard solved durability, not discovery.

Two different drugs, one persistent confusion

The synthetic copy of exendin-4 became exenatide — the drug Byetta, approved by the FDA in 2005 and genuinely historic as the first GLP-1 drug. That is the venom molecule's real descendant.

Ozempic's molecule, semaglutide, is a different compound entirely: a synthetic analogue of human GLP-1, engineered in a laboratory by modifying the human sequence so it survives in the body. No lizard ingredient, no venom, no animal source. The lizard's role in semaglutide's story is ancestral, not material: exenatide proved the receptor was worth targeting and that durability was the problem to solve. Chemists then solved durability their own way, on the human molecule.

And one reasoning error, free of charge

The viral version usually ends with a flourish: since your body makes GLP-1 anyway, these medicines are basically just topping up a natural hormone. That is not a fact; it's an inference, and it fails. Your GLP-1 arrives in brief pulses after meals and is destroyed in about two minutes. An engineered analogue designed to keep signalling for a week is not a top-up — it is a deliberate redesign of the signal's timing. That redesign is exactly why it works as a medicine, and exactly why its effects can't be read off from what the natural hormone does. Natural origin, engineered behaviour. Both halves matter.

"Naturally occurring" tells you where a molecule comes from. It does not tell you what happens when the same signal is supplied from outside, at exposures the body would never produce on its own, for durations it would never sustain. Origin is a fact. Safety is a measurement. A good story is not allowed to merge them.

The accurate version of this story loses none of the drama — lone researcher, unlikely animal, industry-changing drug class. Keep the timeline in your pocket — 1980s: the hormone. Early 1990s: the durable mimic. 2005: the first drug — and you'll spot the garbled version on sight, every time.